Cargando…

Pharmacotherapy of Anxiety Disorders: Current and Emerging Treatment Options

Mostrar otras versiones (1)

Anxiety disorders are the most prevalent psychiatric disorders and a leading cause of disability. While there continues to be expansive research in posttraumatic stress disorder (PTSD), depression and schizophrenia, there is a relative dearth of novel medications under investigation for anxiety diso...

Descripción completa

Detalles Bibliográficos
Autores principales:	Garakani, Amir, Murrough, James W., Freire, Rafael C., Thom, Robyn P., Larkin, Kaitlyn, Buono, Frank D., Iosifescu, Dan V.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Psychiatry
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7786299/ https://www.ncbi.nlm.nih.gov/pubmed/33424664 http://dx.doi.org/10.3389/fpsyt.2020.595584

Ejemplares similares

Pharmacotherapy of Anxiety Disorders: Current and Emerging Treatment Options
por: Garakani, Amir, et al.
Publicado: (2021)

Editorial: Pharmacotherapy of Anxiety Disorders: Promises and Pitfalls
por: Garakani, Amir, et al.
Publicado: (2021)

An umbrella review on the use of antipsychotics in anxiety disorders: A registered report protocol
por: Garakani, Amir, et al.
Publicado: (2022)

The mediating effects of quality of life, depression, and generalized anxiety on perceived barriers to employment success for people diagnosed with Neurofibromatosis Type 1
por: Buono, Frank D., et al.
Publicado: (2021)

Editorial: Assessing and evaluating the impact of the COVID-19 pandemic on anxiety and stress: perspectives from North America
por: Salehi, Mona, et al.
Publicado: (2023)

Protocol for a Pragmatic Trial of Pharmacotherapy Options Following Unsatisfactory Initial Treatment in OCD (PROCEED)
por: Wang, Pei, et al.
Publicado: (2022)

Disparities in program enrollment and employment outcomes for veterans with psychiatric and co-occurring substance use disorders referred or enrolled for VHA vocational rehabilitation
por: Sprong, Matthew E., et al.
Publicado: (2023)

Intensive Dialectical Behavior Treatment for Individuals With Borderline Personality Disorder With and Without Substance Use Disorders
por: Buono, Frank D., et al.
Publicado: (2021)

Current Limitations and Candidate Potential of 5-HT7 Receptor Antagonism in Psychiatric Pharmacotherapy
por: Okubo, Ruri, et al.
Publicado: (2021)

Pharmacotherapy for Alcohol Use Disorders: Physicians’ Perceptions and Practices
por: Ponce Martinez, Caridad, et al.
Publicado: (2016)

A Comparison of Cognitive-Behavioral Therapy and Pharmacotherapy vs. Pharmacotherapy Alone in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)—A Randomized Controlled Trial
por: Corbisiero, Salvatore, et al.
Publicado: (2018)

Novel Pharmacotherapies for Recurrent Pericarditis: Current Options in 2020
por: Tombetti, Enrico, et al.
Publicado: (2020)

Current and Emerging Pharmacotherapy for Fibromyalgia
por: Tzadok, Roie, et al.
Publicado: (2020)

Impact of Substance Use Disorder Pharmacotherapy on Executive Function: A Narrative Review
por: Butler, Kevin, et al.
Publicado: (2019)

The Association of P300 Components With Clinical Characteristics and Efficacy of Pharmacotherapy in Alcohol Use Disorder
por: Yuan, Jing, et al.
Publicado: (2022)

Pharmacotherapy of anxiety disorders: a critical review
por: Koen, Nastassja, et al.
Publicado: (2011)

The use of the Psychiatric Electroencephalography Evaluation Registry (PEER) to personalize pharmacotherapy
por: Iosifescu, Dan V, et al.
Publicado: (2016)

Treatment Combinations for Alzheimer’s Disease: Current and Future Pharmacotherapy Options
por: Cummings, Jeffrey L., et al.
Publicado: (2019)

Pharmacotherapy Options in Rheumatoid Arthritis
por: Kumar, Pradeep, et al.
Publicado: (2013)

The Use of Cognitive Screening in Pharmacotherapy Trials for Cognitive Impairment Associated With Schizophrenia
por: Cotter, Jack, et al.
Publicado: (2019)

The effectiveness of exposure and response prevention combined with pharmacotherapy for obsessive-compulsive disorder: A systematic review and meta-analysis
por: Mao, Lingyun, et al.
Publicado: (2022)

Pharmacotherapy for anxiety disorders in children and adolescents
por: Kodish, Ian, et al.
Publicado: (2011)

Evidence-Based Pharmacotherapy of Generalised Anxiety Disorder: Focus on Agomelatine
por: Stein, Dan J.
Publicado: (2021)

Current and Emerging Pharmacotherapies for Primary CNS Lymphoma
por: Prodduturi, Prathima, et al.
Publicado: (2012)

Pharmacotherapy for uveitis: current management and emerging therapy
por: Barry, Robert J, et al.
Publicado: (2014)

Inter-class Concomitant Pharmacotherapy in Medicaid-Insured Youth Receiving Psychiatric Residential Treatment
por: Edelsohn, Gail A., et al.
Publicado: (2021)

Prediction of Suicidality According to Serum Folate Levels in Depressive Patients Receiving Stepwise Pharmacotherapy
por: Kim, Jae-Min, et al.
Publicado: (2021)

Comorbidity of Obsessive-Compulsive Disorder and Schizotypal Personality Disorder: Clinical Response and Treatment Resistance to Pharmacotherapy in a 3-Year Follow-Up Naturalistic Study
por: Perris, Francesco, et al.
Publicado: (2019)

Pharmacotherapy of Patients Taking New Psychoactive Substances: A Systematic Review and Analysis of Case Reports
por: Ordak, Michal, et al.
Publicado: (2021)

Association Between Current Physical Activity and Current Perceived Anxiety and Mood in the Initial Phase of COVID-19 Confinement
por: López-Bueno, Rubén, et al.
Publicado: (2020)

Corrigendum: Association Between Current Physical Activity and Current Perceived Anxiety and Mood in the Initial Phase of COVID-19 Confinement
por: López-Bueno, Rubén, et al.
Publicado: (2021)

Current status of post-traumatic stress disorder among emergency nurses and the influencing factors
por: Qian, Yu-Fei, et al.
Publicado: (2023)

New pharmacotherapy options for noninfectious posterior uveitis
por: Pleyer, Uwe, et al.
Publicado: (2021)

Association between temporomandibular disorders and anxiety: A systematic review
por: dos Santos, Erick Alves, et al.
Publicado: (2022)

T198. CAN AUGMENTED SUBLINGUAL OXYTOCIN DECREASE NEGATIVE SYMPTOMS WITHIN TREATMENT RESISTANT SCHIZOPHRENIC POPULATIONS: A PILOT STUDY
por: Marotta, Rocco, et al.
Publicado: (2020)

Suicide Screening Tools for Pediatric Emergency Department Patients: A Systematic Review
por: Scudder, Amanda, et al.
Publicado: (2022)

Methylphenidate as a treatment option for substance use disorder: a transdiagnostic perspective
por: van Ruitenbeek, Peter, et al.
Publicado: (2023)

Depression and Anxiety as Key Factors Associated With Quality of Life Among Lung Cancer Patients in Hai Phong, Vietnam
por: Khue, Pham Minh, et al.
Publicado: (2019)

Increased anxiety from fear of Omicron in China as compared to North America and Western Europe: A cross-sectional Kendall’s tau-b analysis using the generalized anxiety disorder 7-item questionnaire
por: Shan, Dan, et al.
Publicado: (2022)

Editorial: Neuroimaging Biomarkers in Mood and Anxiety Disorders
por: Lai, Chien-Han, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_6uml3e5p405romdaf6sc028og6